Mylotarg Injection, Powder, Lyophilized, For Solution
Product Images NDC 0008-4510

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Mylotarg (NDC 0008-4510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Mylotarg 01)

An illustration depicting the molecular structure of gemtuzumab conjugate components, including a schematic antibody representation labeled 'Gemtuzumab,' a chemical linker structure, and a complex chemical structure labeled 'N-Acetyl Calicheamicin.' The image shows the covalent linkage between these parts forming the conjugate, with an annotation indicating an average polymerization degree of 2 to 3.*

FDA Label Image

Figure 1 (Mylotarg 02)

A Kaplan-Meier survival curve depicting survival probability over time in months for two cohorts: one receiving gemtuzumab ozogamicin combined with daunorubicin and cytarabine (GO + D + C) and another receiving daunorubicin and cytarabine alone (D + C). The graph includes censored observations marked with circles and tables of numbers at risk below the x-axis.*

FDA Label Image

Figure 2 (Mylotarg 03)

A Kaplan-Meier survival curve comparing survival probability over time (months) between two groups labeled GO and No GO. The plot includes censoring marks for both groups, showing survival trends up to approximately 75 months. The x-axis represents survival time in months, and the y-axis indicates survival probability. The number at risk is provided below the graph for both groups at specified time points.*

FDA Label Image

Logo (Mylotarg 04)

FDA Label Image

Principal Display Panel (4.5 mg Vial Label)

Packaging label for Mylotarg 4.5 mg vial, an injection containing gemtuzumab ozogamicin. The label indicates the product is for intravenous infusion only, single-dose vial with no preservatives, and directs disposal of unused portions. It is manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Storage instructions specify refrigeration at 2°C to 8°C and protection from light.*

FDA Label Image

Principal Display Panel (4.5 mg Vial Carton)

Packaging label for Mylotarg 4.5 mg/vial (gemtuzumab ozogamicin) injection, powder, lyophilized, for solution. The label shows it is for intravenous infusion only, requires reconstitution, and contains no preservatives. Manufactured by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary. The label includes storage instructions to refrigerate at 2°C to 8°C and other handling details. The design features a yellow background with Pfizer logos and multiple barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.